Drugs.com - New Drug Approvals

FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatment of Cutaneous Squamous Cell Carcinoma

WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration ("FDA") has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults...

Feb 9, 2025 - 22:25
 0
FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatment of Cutaneous Squamous Cell Carcinoma
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration ("FDA") has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults...
Read More

Tags:

Previous Article

FDA Approves Crenessity (crinecerfont) for the Treatment of Children and Adults ...

Next Article

Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients ...

Related Posts

FDA Approves Crenessity (crinecerfont) for the Treatment of Children and Adults with Classic Congenital Adrenal Hyperplasia

FDA Approves Crenessity (crinecerfont) for the Treatmen...

Feb 9, 2025  0

Spravato (esketamine) Approved in the U.S. as the First and Only Monotherapy for Adults with Treatment-Resistant Depression

Spravato (esketamine) Approved in the U.S. as the First...

Feb 9, 2025  0

FDA Approves Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

FDA Approves Symbravo (meloxicam and rizatriptan) for t...

Feb 9, 2025  0